Actively Recruiting

Age: 5Years - 75Years
All Genders
ID05973084

COVID-19 Transmission and Morbidity in Malawi

Led by Boston University · Updated on 2026-05-28

1500

Participants Needed

2

Research Sites

N/A

Total Duration

On this page

Sponsors

B

Boston University

Lead Sponsor

N

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are investigating why the impact of SARS-CoV-2 in sub-Saharan African countries, specifically Malawi, appears milder compared to Europe and the Americas. The study aims to understand how innate immune responses, malaria, intestinal parasites, undernutrition, and anemia influence infection risk, symptom progression, transmission, and responses to SARS-CoV-2 vaccination. They are assessing immune responses and vaccine effects in various groups to better understand susceptibility and immunity in this population. The study includes up to 200 symptomatic individuals confirmed with SARS-CoV-2 infection, their household contacts (about 700), and up to 600 vaccine recipients aged 5 to 75 years. Participants undergo multiple visits for blood and stool sample collection over a follow-up period of up to 1.5 years. Vaccine recipients receive either the AstraZeneca or Johnson and Johnson vaccines, with samples collected at specific intervals after vaccination to monitor immune responses. Participants will have blood drawn at baseline and multiple follow-up visits to measure antibody levels, cellular immune responses, and markers of inflammation. Stool samples will be collected to diagnose intestinal parasites. Researchers will also monitor infection rates, symptom duration, and vaccine responses. The study will track these measures over time to assess how infections and vaccinations affect immunity and disease outcomes, with the overall participation lasting up to 15 months after initial enrollment.

CONDITIONS

Brief Title

COVID-19 Transmission and Morbidity in Malawi

Who Can Participate

Age: 5Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Presents with symptoms of COVID-19 and has infection confirmed by RT-PCR or rapid antigen test (index cases)
  • Aged 5 to 75 years and plans to live in Blantyre catchment area for at least 6 months
  • Confirmed SARS-CoV-2 infection and shares a household with eligible individuals (index cases)
  • Has not received a SARS-CoV-2 vaccine in the previous 3 months (index cases and household contacts)
  • Willingness to comply with study procedures and provides informed consent
  • Household contacts aged 5 to 75 years living in Blantyre catchment area and willing to comply with study visits
  • Vaccinees aged 18 to 75 years willing to receive AstraZeneca or Johnson and Johnson vaccines
  • Has not received any prior SARS-CoV-2 vaccine dose (vaccinees)
Not Eligible

You will not qualify if you...

  • Conditions preventing adherence to visit schedule
  • 50% or more of household members decline participation (index cases)
  • Pregnancy at enrollment visit
  • Long-term use of cotrimoxazole prophylaxis
  • Participants with 2 consecutive negative SARS-CoV-2 RT-PCRs excluded from visits after month 1 (household contacts)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Up to 1.5 years

Participants are observed with repeated blood and stool sample collections to assess immune responses and infection status over time.

Multiple visits including blood and stool sample collections at baseline, 2 weeks, 15 days, 1 month, 3 months, 6 months, 9 months, 12 months, and 15 months depending on cohort

Trial Site Locations

Total: 2 locations

1

BU School of Public Health, Global Health Department

Boston, Massachusetts, United States, 02118

Active, Not Recruiting

2

Health center

Blantyre, Malawi

Actively Recruiting

Loading map...

Research Team

C

Clarissa Valim, MD ScD

A

Aditi S Kothari, BDS MDSc MPH

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

Cardiovascular Autonomic and Immune Mechanism of Post COVID-...

Post-acute COVID-19 Syndrome

Actively Recruiting

1 location

Mechanism of Isolevuglandin-Protein Adduct Formation in Pers...

Post-Acute COVID-19 Syndrome

Actively Recruiting

1 location

Revamping Exercise Assessments in Child Health (Project REAC...

Cystic Fibrosis

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here